More Post from the Author
- ePlus Announces Fourth Quarter and Fiscal Year 2026 Earnings Release Date and Conference Call
- AARP Mississippi Applauds Passage and Signing of law to Protect Consumers from Cryptocurrency Kiosk Fraud
- Use.AI Launches Unified AI Workspace Platform to Improve Daily Workflows
- Sandbox VR Continues to Expand Presence with New Location in Miami, Opening June 10
- Club Offers for Travel Enthusiasts in the UK
Alvogen Issues Voluntary Nationwide Recall for One Lot of Fentanyl Transdermal System 25 mcg/h Due to a Defective Delivery System
Published on Mon 3 Feb 2025 2:31:05 UTC
Company Contact Information
Consumers:
866-770-3024
[emailprotected]
Press:
[emailprotected]
MORRISTOWN, N.J., Jan. 31, 2025 /PRNewswire/ -- Alvogen, Inc. is voluntarily recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches to the consumer level. The reason for the recall is that there is a potential that patches could be multi-stacked, adhered one on top of the other, in a single product pouch. This transdermal system is manufactured by Kindeva Drug Delivery L.P., Northridge, CA and is distributed by Alvogen, Inc. as a private label distributor.
More Post from the Author
- ePlus Announces Fourth Quarter and Fiscal Year 2026 Earnings Release Date and Conference Call
- AARP Mississippi Applauds Passage and Signing of law to Protect Consumers from Cryptocurrency Kiosk Fraud
- Use.AI Launches Unified AI Workspace Platform to Improve Daily Workflows
- Sandbox VR Continues to Expand Presence with New Location in Miami, Opening June 10
- Club Offers for Travel Enthusiasts in the UK





